Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: A 7-day dose-ranging study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 63, Issue 1, 2008, Pages 103-111

  LaForce, C ^a   Alexander, M ^b   Deckelmann, R ^c   Fabbri, L M ^d   Aisanov, Z ^e   Cameron, R ^f   Owen, R ^f   Higgins, M ^f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c Dr Gerald Eckhardt Internisten Lungen und Bronchialheilkunde Allergologie   (Germany)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e Research Institute of Pulmonology   (Russian Federation)

^f NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Asthma; Bronchodilator; Efficacy; Indacaterol; Long acting 2 agonist

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; INDACATEROL; PLACEBO; SALBUTAMOL;

ADULT; ADVERSE OUTCOME; AGED; ALLERGIC RHINITIS; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; EAR DISEASE; ENDOCRINE DISEASE; ERYTHEMA; EYE DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART PALPITATION; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INHALER; INJURY; INNER EAR DISEASE; INSOMNIA; INTOXICATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PRIORITY JOURNAL; PROCEDURAL SITE REACTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SPIROMETRY; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS TISSUE; TACHYCARDIA; THORAX PAIN; VERTIGO; WHEEZING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; QUINOLONES; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

EID: 36649002044     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2007.01555.x     Document Type: Article

References (27)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2006 NIH Publication No 02-3659 (updated 2006).
2. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997 337 : 1405 1411.
3. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996 153 : 1481 1488.
4. Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 2002 6 (suppl. S554 S559.
5. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 23 : 1296 1310.
6. Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000 106 : 485 492.
7. Masoli M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily administration: meta-analysis. Respirology 2004 9 : 528 534.
8. 2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007 29 : 871 878.
9. Chuchalin AG, Tsoi AN, Richter K, Krug N, Dahl R, Luursema PB et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 2007 101 : 2065 2075.
10. Quanjer Ph H, Tammeling GJ, Cotes JE, Pedersen OJF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J 1993 6 (suppl. 16 5 40.
11. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995 152 : S77 S120.
12. Huhti E, Poukkula A. Clinical comparison of fenoterol and albuterol administered by inhalation. A double-blind study. Chest 1978 73 : 348 351.
13. van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996 9 : 1684 1688.
14. 2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study. Eur Respir J 2005 26 (suppl. 49 253s, P1729.
15. Crane J, Burgess C, Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol and isoprenaline. Thorax 1989 44 : 136 140.
16. Maconochie JG, Forster JK. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol 1992 33 : 342 345.
17. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol and terbutaline in asthma. Lancet 1990 336 : 1396 1399.
18. Cheong B, Reynolds SR, Rajan G, Ward MJ. Intravenous beta agonist in severe acute asthma. Br Med J 1988 297 : 448 450.
19. Lofdahl CG, Sigvaldasson A, Skoogh BE, Svedmyr N. Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment. Respiration 1989 55 (suppl. 2 15 19.
20. Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf 2004 27 : 689 715.
21. Sears MR, Lotvall J. Past, present and future - beta2-adrenoceptor agonists in asthma management. Respir Med 2005 99 : 152 170.
22. Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med 2003 2 : 287 297.
23. Totterman KJ, Huhti L, Sutinen E, Backman R, Pietinalho A, Falck M et al. Tolerability to high doses of formoterol and terbutaline via turbuhaler for 3 days in stable asthmatic patients. Eur Respir J 1998 12 : 573 579.
24. Kruse M, Rosenkranz B, Dobson C, Ayre G, Horowitz A. Safety and tolerability of high-dose formoterol (aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma. Pulm Pharmacol Ther 2005 18 : 229 234.
25. Malolepszy J, Boszormenyi Nagy G, Selroos O, Larsso P, Brander R. Safety of formoterol turbuhaler at cumulative dose of 90 micrograms in patients with acute bronchial obstruction. Eur Respir J 2001 18 : 928 934.
26. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lotvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol 2000 56 : 363 370.
27. Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002 6 (suppl. S322 S328.